Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

J Clin Oncol · 2020 · PMC7768340 · PMID 32986498

Europe PMC DOI

hedged sentences

0.2900

closest p · 5.8× alpha

0.2900

boldest claim

The sentences

showed a trendP = .29not close (p > 0.1)

Patients with high-GC status showed a trend toward inferior PFS versus those with low-GC status (HR, 1.5; 95% CI, 0.7 to 3.4; P = .29).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Within the VenR cohort, despite the observed differences in uMRD rates, a trend for inferior PFS was observed only in patients with del(17p13.1); however, the difference did not reach statistical significance in multivariable adjustment (Figs 4 B and 4 C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.